MetaCap

Oragenics (OGEN) vs China SXT Pharmaceuticals (SXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oragenics is the larger company by market cap ($708,377 vs $273,955), about 2.6 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OGEN-68.59%SXTC-6.54%
+36%-34%-105%
Oct 7, 20261 yearNov 20, 2026
OGEN-65.57%SXTC+1678.75%
+2194%+1007%-180%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OGEN versus SXTC key metrics
MetricOGENSXTC
Share price$0.157$2.65
Market cap$708.38K$273.95K
1-day change-8.72%+2.12%
EPS (TTM)$-1.05$-73,040.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.14M
Revenue growth (YoY)—-34.63%
Net income (latest FY)$-9.84M$-6.21M
Gross margin—21.85%
Operating margin—-625.89%
Net margin—-545.24%
52-week high$1.11$8,376,000.00
52-week low$0.13$2.52
Distance from 52-week high-85.86%-100.00%
Average volume849.30K234.25K
Shares outstanding4.51M103.58K
Employees356
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Oragenics is about 2.6 times larger than China SXT Pharmaceuticals by market value ($708.38K vs $273.95K).

About Oragenics

OGEN stock →

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About China SXT Pharmaceuticals

SXTC stock →

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

OGEN vs SXTC FAQ

Which is bigger, Oragenics or China SXT Pharmaceuticals?

Oragenics (OGEN) is larger, with a market capitalization of $708.38K compared with $273.95K for China SXT Pharmaceuticals (SXTC).

Are Oragenics and China SXT Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons